NCT05419050View on ClinicalTrials.gov

Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

January 9, 2026

Study Completion Date

January 9, 2026

Conditions
Fibrous Dysplasia
Interventions
DRUG

denosumab

monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Dental and Craniofacial Research (NIDCR)

NIH